FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OWR APPRO	VAL
OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Richman Michael  (Last) (First) (Middle)  C/O PIERIS PHARMACEUTICALS, INC.  255 STATE STREET, 9TH FLOOR						2. Issuer Name and Ticker or Trading Symbol PIERIS PHARMACEUTICALS, INC. [ PIRS ]  3. Date of Earliest Transaction (Month/Day/Year) 10/25/2017  4. If Amandment, Date of Original Filed (Marth/Day/Year)								(Che	Relationship of Reporting Persor theck all applicable)  X Director Officer (give title below)			10% Ov Other (s below)	vner
(Street) BOSTON MA 02109 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								Line) X	X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						ction 2A. Deemed Execution Date			3. Transaction		4. Securities Acquired (A Disposed Of (D) (Instr. 3,		red (A)	or 5. Amou 4 and Securiti Benefici Owned I		int of 6. C es For ially (D) Following (I) (		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D) Price			Transact (Instr. 3	Reported Transaction(s) Instr. 3 and 4)			(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exc Expiration (Month/Da	Date		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			. Price of lerivative lecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	i lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)
					Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amo or Num of Sha	nber					
Stock Option (Rights to buy)	\$4.68	10/25/2017			A		4,006		10/25/201	7 1	0/25/2027	Common Stock	4,0	006	\$0.00	4,006		D	

**Explanation of Responses:** 

Remarks:

/s/ Marc D. Mantell, Attorney-10/27/2017 in-fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.